23009-97-4

Basic information

• Product Name: (2S)-2-[(PHENOXYACETYL)AMINO]PROPANOIC ACID
• Synonyms: Alanine,N-(phenoxyacetyl)-, L- (8CI)
• CAS NO: 23009-97-4
• Molecular Formula: C₁₁H₁₃NO₄
• Molecular Weight: 0
• Mol File: 23009-97-4.mol

Chemical Properties

• Boiling Point: 489.8°Cat760mmHg
• Flash Point: 250°C
• Appearance: /
• Density: 1.237g/cm³
• Vapor Pressure: 2.07E-10mmHg at 25°C
• CAS DataBase Reference: (2S)-2-[(PHENOXYACETYL)AMINO]PROPANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: (2S)-2-[(PHENOXYACETYL)AMINO]PROPANOIC ACID(23009-97-4)
• EPA Substance Registry System: (2S)-2-[(PHENOXYACETYL)AMINO]PROPANOIC ACID(23009-97-4)

Safety Data

• Hazardous Substances Data: 23009-97-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Flurbiprofen is used as an analgesic and anti-inflammatory agent for the treatment of conditions such as rheumatoid arthritis, osteoarthritis, and other musculoskeletal disorders. It is effective in managing mild to moderate pain and reducing inflammation, thereby improving the quality of life for patients suffering from these conditions.
Used in Pain Management:
Flurbiprofen is utilized as a pain management tool for individuals experiencing mild to moderate pain. Its ability to reduce inflammation and alleviate pain makes it a suitable option for various types of discomfort, including post-operative pain and menstrual cramps.
Used in Topical Formulations:
In addition to oral administration, flurbiprofen is also available in topical formulations, allowing for localized pain relief. This is particularly beneficial for individuals with specific areas of pain or inflammation that do not require systemic treatment.
However, it is important to note that flurbiprofen, like other NSAIDs, can cause side effects such as gastrointestinal ulcers, bleeding, and kidney problems. Therefore, it should be used with caution in individuals with a history of these conditions.

InChI:InChI=1/C11H13NO4/c1-8(11(14)15)12-10(13)7-16-9-5-3-2-4-6-9/h2-6,8H,7H2,1H3,(H,12,13)(H,14,15)/p-1/t8-/m1/s1

Upstream product

• 701-99-5 Phenoxyacetyl chloride 
• 302-72-7 rac-Ala-OH 
• 56-41-7 L-alanin 
• 23009-97-4 N-phenoxyacetyl-DL-alanine 

Downstream Products

• 23009-97-4 (S)-2-(2-phenoxyacetamido)propanoic acid 
• 184916-07-2 (S)-N-Methoxy-N-methyl-2-(2-phenoxy-acetylamino)-propionamide 
• 192378-09-9 (S)-3-amino-N-phenoxyacetylbutanone 
• 184916-09-4 2-Phenoxy-N-((S)-3,3,3-trifluoro-2-hydroxy-1-methyl-propyl)-acetamide 
• 184916-08-3 N-((S)-1-Methyl-2-oxo-ethyl)-2-phenoxy-acetamide 
• 227020-19-1 (R,S)-O-benzyl-N-phenoxyacetylalanine hydroxamate 

Relevant articles and documents

Solid-Phase Synthesis of 4-Arylazetidin-2-ones via Suzuki and Heck Cross-Coupling Reactions

Application of the Suzuki and the Heck cross-coupling reactions for efficient synthesis of diverse biaryl- and styryl-substituted β-lactams on solid support using an optimized catalyst system is reported. The coupling of phenylboronic acid with the resin-bound 3-phenoxy-4-iodophenyl β-lactam 1a proceeded in 89% isolated yield by employing 20 mol % of the bidentate phosphine-palladium complex, [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride {PdCl2(dppf)} as catalyst in the presence of triethylamine (TEA, 10 equiv) in DMF at 65 °C for 12 h. Efficient cross-coupling of the iodophenyl β-lactam to heterocyclic boronates and aryl boronates substituted with various electron-donating and -withdrawing groups is also demonstrated. The reverse coupling reactions of immobilized arylboronic acid le with a variety of substituted aryl iodides were found to proceed in excellent yields using the same catalyst system in a 3/7 mixture (v/v) of H2O:DMF at 40 °C. The use of this catalyst for the vinylation of aryl iodide la via the Heck reaction was also examined.

Fragment-based drug design targeting syntenin PDZ2 domain involved in exosomal release and tumour spread

Syntenin stimulates exosome production and its expression is upregulated in many cancers and implicated in the spread of metastatic tumor. These effects are supported by syntenin PDZ domains interacting with syndecans. We therefore aimed to develop, throu

PROCESS FOR THE SEPARATION OF RACEMIC MIXTURES

The present invention relates to a process for the separation of racemic mixtures comprising development of a denser molecular imprint on silica with a desired enantiomer by sol-gel-protocol comprising hydrolytic control polymerization of a silica source as the monomer and amino alkylsilane as a functional monomer in the presence of the desired enantiomer, capping of surface OH groups and desorption of ancapsulated enantiomer from the silica.

Synthesis of metallo-β-lactamase inhibitors

α-Amido trifluoromethyl alcohols and ketones were synthesised via two independent routes using the Ruppert Reagent (TMS-CF3) and shown to be inhibitors of metallo-β-lactamases.

Trifluoromethyl alcohol and ketone inhibitors of metallo-β-lactamases

α-Amido trifluoromethyl alcohols and ketones were synthesised via two independent routes using Ruppert's Reagent (TMS-CF3) and shown to be the first reported synthetic inhibitors of metallo-β-lactamases.